Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market

COLLEGE STATION, TX / ACCESSWIRE / February 21, 2022 / Enzolytics, Inc. (OTC PINK: ENZC) (https://enzolytics.com/) announces its plans to enter the diagnostic market. Enzolytics has filed a full patent application in the U.S. Patent Cooperation Treaty (PCT), which covers the invention of a new innovative technology for improved diagnostics. The PCT application covers the Company’s identification of highly conserved SARS-CoV-2 antigens and epitopes that can be used in vaccines and for the production of binding proteins (eg antibodies) for the treatment, prevention or reduction of risk of β-coronavirus-CoV infections such as SAR 2. The patent also covers the discovery of the use of these detected antigens and epitopes as targets for the detection and diagnosis of SARS-CoV-2 infection.

The company’s artificial intelligence platform was used to create 3D models of saved targets. Analysis of the SARS-CoV-2 thorn protein showed that all epitopes identified by the Company are linear with respect to adhesion proteins, available antibodies, neutralized, and unaffected by mutations.

The company’s findings provide a framework for addressing the problem caused by the rapid evolution of SARS-CoV-2 variants that have mutations in genomic and protein sequences, which prevents the development of effective methods for accurate infection detection. The impact of mutations on test performance can be influenced by several factors, including variant sequence (including number, identity, and location of mutations), test design, and variant prevalence in the population. For example, single-purpose tests are unlikely to be able to detect new options. On the other hand, tests for several purposes (for example A PCR test designed to detect more than one region of the SARS-CoV-2 genome, or an antigen test designed to detect more than one region of an adhesion protein) can more accurately detect new variants. For example, it is expected that a molecular test capable of detecting other variants will not detect a variant of SARS-CoV-2 Omicron (B.1.1.529) due to a deletion of nine nucleotides in the N-gene covering positions 28370-28362, in that while as a test for dual-target antigens, capable of detecting other variants is not expected to detect the Omicron variant due to deletions at amino acid positions 69-70 and mutations at nucleotide positions 23599.

Enzolytics is developing tests that diagnose SARS-CoV-2 based on the presence of preserved sites that remain intact mutations. Using artificial intelligence technology, all canned objects identified by the Company remained present in all options of concern and options of interest.

Enzolytics is currently collaborating with diagnostic companies that have recommendations on the use of this technology and tests conducted in accordance with it through the approval of regulators, leading to patient use.

Global in vitro the diagnostics market was estimated at approximately $ 68.41 billion in 2020. The market value is expected to increase to $ 91.25 billion in revenue in 2026 with an average growth of 4.90% over the forecast period.

She drew attention to the COVID-19 pandemic in vitro diagnosis. As a result, there is a growing demand for kits for IVD and reagents for the rapid and accurate diagnosis of SARS-CoV-2 virus infection among the global population. The COVID-19 outbreak is expected to have a positive impact on the market studied as well in vitro diagnosis involves the study of various biological samples. This is expected to help diagnose infectious diseases such as COVID-19. Thus, testing remains a crucial step in the fight against the COVID-19 pandemic. As a result, the impetus for a faster, more reliable and accurate diagnosis of SARS-CoV-2 is amplified. The company’s new technology addresses this need.

This new technology is an adjunct and addition to the company’s many technology platforms, which include:

Immunomodulator IPF Immune ™ enters the US market in March.

The company is developing the therapeutic drug ITV-1 for the treatment of HIV.

The company produces monoclonal antibodies against HIV.

The company produces monoclonal antibodies against SARS CoV-2.

The company has planned to produce monoclonal antibodies to fight animal viruses such as equine infectious anemia virus, feline leukemia virus, feline immunodeficiency virus, equine herpesvirus (EHV), koala retrovirus (KoRV) and endotheliotropic Herpesvirus endothelial herpesvirus.

The company’s artificial intelligence (AI) platform, including:

AI analysis to identify unchanged sites. 3D epitope modeling to establish linearity, neutralizing potential, and antibody availability.

AI to assess the impact of nutrition, genetics and microbiome on disease:

  • Build models for predicting infectious diseases (predominantly COVID), mental health disorders, and chronic diseases.

  • Identify biomarkers of infectious and chronic diseases.

  • Identify new goals and clear intervention strategies for infectious and chronic diseases.

AI Platform for genomic surveillance, viral epidemiology monitoring.

About Enzolytics, Inc.

Enzolytics, Inc. is a drug development company that commercializes its patented proteins and monoclonal antibodies to treat debilitating infectious diseases. The company promotes a variety of therapeutic agents aimed at many infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of inactivated pepsin fraction (IPF), covered by U.S. Patents № 8,066,982 and 7,479,538. Studies have shown that it is effective in treating HIV / AIDS. ITV-1 has also been shown to modulate the immune system.

The company is also introducing its patented technology to produce fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus and diphtheria. Its patented methodology, which is considered in a U.S. patent application for the production of fully human monoclonal antibodies, is currently used to produce monoclonal antibodies for the treatment of many infectious diseases, including coronavirus (SARS-CoV-2) and HTLV-1.

Safe Harbor Statement: This news release contains forward-looking statements that include risks and uncertainties related to financial projections, budgets, milestones, clinical development, regulatory approvals, and other risks that are occasionally described by Enzolytics, Inc. in its periodic reports submitted to the SEC. ITV-1 is not approved by the U.S. Food and Drug Administration or any similar regulatory body in the rest of the world.

Although Enzolytics, Inc. believes that the forward-looking statements and the underlying assumptions contained in them are reasonable, any of the assumptions may be inaccurate, including, but not limited to, Enzolytics’ ability to establish the effectiveness of its therapeutic agents in treating any disease or health, developing research and strategies leading to the commercialization of its therapeutic agents in the United States, obtaining the funding needed to implement a development plan, completing research and tests in a timely manner or in general, and successfully completing the results of such research or tests. Therefore, there can be no assurance that the forward-looking statements included in this issue will be accurate.

Such forward-looking statements are based on current expectations. These include inherent risks and uncertainties, including factors that may delay, delay or alter any statements made and result in actual results and outcomes differing materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements were made on the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or to update the reasons why the actual results may differ from those projected in the forward-looking statements.

IR contact:
TEN Associates, LLC
Tom Nelson, CEO
(480) 326-8577

Company contact:
Enzolytics, Inc.
2000 North Central Expressway
Plana, Texas 75074

SOURCE: Enzolytics, Inc.

View original on accesswire.com:

Leave a Comment